Characteristics and management of myelosuppression TEAEs
| Parameter . | All grades . | Grade 3/4 . | |||
|---|---|---|---|---|---|
| CP2L (n = 157) . | CP3L (n = 56) . | ADV (n = 106) . | Total (n = 319) . | Total (n = 231) . | |
| Median time to first event (range), d | 29.0 (1-1767) | 28.0 (1-1202) | 14.0 (1-899) | 22.0 (1-1767) | 29.0 (1-1767) |
| Median duration of an event (range), d | 15.0 (1-1373) | 15.0 (1-454) | 8.0 (1-889) | 14.0 (1-1373) | 9.0 (1-889) |
| Myelosuppression resolved, n (%) | 85 (54) | 34 (61) | 52 (49) | 171 (54) | 163 (71) |
| Myelosuppression management, n (%) | |||||
| Received dose reduction | 56 (36) | 21 (38) | 25 (24) | 102 (32) | 60 (26) |
| Received dose interruption | 74 (47) | 33 (59) | 38 (36) | 145 (46) | 138 (60) |
| Received concurrent medication | 22 (14) | 13 (23) | 26 (25) | 61 (19) | 46 (20) |
| Received transfusion(s) | 0 | 1 (2) | 1 (1) | 2 (1) | 1 (<1) |
| Received growth factor(s) | 10 (6) | 10 (18) | 13 (12) | 33 (10) | 26 (11) |
| Permanent treatment discontinuation due to myelosuppression* | 20/286 (7) | 14/118 (12) | 6/166 (4) | 40/570 (7) | 33/570 (6) |
| Parameter . | All grades . | Grade 3/4 . | |||
|---|---|---|---|---|---|
| CP2L (n = 157) . | CP3L (n = 56) . | ADV (n = 106) . | Total (n = 319) . | Total (n = 231) . | |
| Median time to first event (range), d | 29.0 (1-1767) | 28.0 (1-1202) | 14.0 (1-899) | 22.0 (1-1767) | 29.0 (1-1767) |
| Median duration of an event (range), d | 15.0 (1-1373) | 15.0 (1-454) | 8.0 (1-889) | 14.0 (1-1373) | 9.0 (1-889) |
| Myelosuppression resolved, n (%) | 85 (54) | 34 (61) | 52 (49) | 171 (54) | 163 (71) |
| Myelosuppression management, n (%) | |||||
| Received dose reduction | 56 (36) | 21 (38) | 25 (24) | 102 (32) | 60 (26) |
| Received dose interruption | 74 (47) | 33 (59) | 38 (36) | 145 (46) | 138 (60) |
| Received concurrent medication | 22 (14) | 13 (23) | 26 (25) | 61 (19) | 46 (20) |
| Received transfusion(s) | 0 | 1 (2) | 1 (1) | 2 (1) | 1 (<1) |
| Received growth factor(s) | 10 (6) | 10 (18) | 13 (12) | 33 (10) | 26 (11) |
| Permanent treatment discontinuation due to myelosuppression* | 20/286 (7) | 14/118 (12) | 6/166 (4) | 40/570 (7) | 33/570 (6) |
Myelosuppression events include anemia, hemoglobin decreased, neutropenia, neutrophil count decreased, thrombocytopenia, and platelet count decreased.
Abbreviations are explained in Table 1.
Includes patients with no rechallenge or unsuccessful rechallenge following dose interruption as well as those who discontinued treatment due to myelosuppression without dose interruption.